German company Bayer is to build a production unit for over-the-countermedicines in Buenos Aires, Argentina, which will be financed by an investment of $40 million.
The consumer care business group will produce around 3.3 billion units per year of Bayer's Aspirin in various dosage forms. The firm also plans to supply the markets in Chile, Bolivia, Paraguay and Uruguay.
The new production plant, which Bayer says will be one of the most modern of its type in the world, will operate to Good Manufacturing Practice standards.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze